<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-43010" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vasodilators</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hariri</surname>
            <given-names>Lana</given-names>
          </name>
          <aff>American University of The Caribbean</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Jayesh B.</given-names>
          </name>
          <aff>University of Iowa Hospitals and Clinics</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lana Hariri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayesh Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-43010.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Vasodilators are useful in the management of hypertension, angina, heart failure, myocardial infarction, and more. This activity reviews the indications, actions, and contraindications for vasodilation therapy as a valuable agent in the treatment of hypertension and other related disorders. This activity will also highlight the mechanism of action, adverse event profile, and other key factors pertinent to members of the interprofessional team in the treatment of patients with hypertension and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of vasoconstriction.</p></list-item><list-item><p>Review the adverse side effects of vasodilator therapy.</p></list-item><list-item><p>Outline the indications of vasodilator therapy.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to advance vasodilator use and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43010&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43010">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-43010.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Vasodilators are useful in treating a variety of medical conditions, most commonly systemic hypertension.<xref ref-type="bibr" rid="article-43010.r1">[1]</xref>&#x000a0;Other diseases include myocardial infarction (both ST-segment elevation and non-ST-segment&#x000a0;elevation), angina, heart failure, stroke, chronic kidney disease, preeclampsia, hypertensive emergency.&#x000a0;There are different&#x000a0;classes of vasodilators used today in the current clinical practice, and each has different actions on the coronary arteries and peripheral&#x000a0;vasculature (arteries and veins).&#x000a0;Vasodilators most commonly affect the arteries in the human body, but some vasodilators (such as nitroglycerin) can affect the venous system of the body predominantly.&#x000a0;</p>
        <p>Several different vasodilators have undergone development over the years, as mentioned below.<xref ref-type="bibr" rid="article-43010.r2">[2]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Direct-acting vasodilators (hydralazine, minoxidil, nitrates, nitroprusside)</p>
          </list-item>
          <list-item>
            <p>Calcium channel blockers (verapamil, diltiazem, nifedipine, amlodipine)</p>
          </list-item>
          <list-item>
            <p>An antagonist of the renin-angiotensin-aldosterone system (angiotensin receptor blockers, angiotensin-converting-enzyme inhibitors)</p>
          </list-item>
          <list-item>
            <p>Beta-2 receptor agonist (salbutamol, terbutaline)</p>
          </list-item>
          <list-item>
            <p>Postsynaptic alpha-1 receptor antagonist (prazosin, phenoxybenzamine, phentolamine)</p>
          </list-item>
          <list-item>
            <p>Centrally acting alpha-2 receptor agonist (clonidine,&#x000a0;&#x003b1;-methyldopa)</p>
          </list-item>
          <list-item>
            <p>Endothelin receptor antagonist (bosentan, ambrisentan)</p>
          </list-item>
          <list-item>
            <p>Phosphodiesterase inhibitors (sildenafil, tadalafil)</p>
          </list-item>
        </list>
        <p>Renin-angiotensin-aldosterone system blockers such as ACE inhibitors and ARBs are first-line of the treatment in patients with heart failure, history of ST-elevation myocardial infarction, diabetes, or proteinuria. Both groups of medications have cardioprotective and renoprotective effects.&#x000a0;</p>
        <p>Clinicians can use many vasodilators in preeclampsia, which is a condition seen in the pregnancy characterized by severe hypertension and proteinuria.&#x000a0;If not treated quickly, patients can develop seizures. ACE Inhibitors and ARBs are contraindicated in pregnancy due to teratogenicity. Hydralazine and calcium channel blockers (amlodipine, nifedipine) are safe to use in these circumstances.</p>
        <p>Many vasodilators are used in hypertensive emergencies and urgencies. Hypertensive emergency is defined as an elevation of systolic blood pressure over 180 mmHg and/or diastolic blood pressure exceeding 120 mmHg with the presence of acute target organ damage (such as kidney insult, encephalopathy, retinal hemorrhage, aortic dissection, subarachnoid hemorrhage). Hypertensive urgencies are defined as an elevation of systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure over 120 mmHg without any clinical or laboratory evidence of acute&#x000a0;end-organ damage.&#x000a0;In hypertensive emergency following drugs are the first choice depending on systemic involvement.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Aortic dissection: intravenous esmolol, intravenous nitroprusside, or nitroglycerine</p>
          </list-item>
          <list-item>
            <p>Acute pulmonary edema:&#x000a0;intravenous&#x000a0;nitroglycerine, nitroprusside, or clevidipine</p>
          </list-item>
          <list-item>
            <p>Acute myocardial infarction/unstable angina:&#x000a0;intravenous esmolol or&#x000a0;nitroglycerine</p>
          </list-item>
          <list-item>
            <p>Acute renal failure:&#x000a0;intravenous fenoldopam, clevidipine, or nicardipine</p>
          </list-item>
          <list-item>
            <p>Eclampsia: intravenous hydralazine, nicardipine, or labetalol</p>
          </list-item>
          <list-item>
            <p>Pheochromocytoma/hyperadrenergic state secondary to amphetamine or cocaine:&#x000a0;intravenous clevidipine, phentolamine, or nicardipine</p>
          </list-item>
        </list>
        <p>This review&#x000a0;will focus more on direct-acting vasodilators, calcium channel blockers, and renin-angiotensin-aldosterone antagonists&#x000a0;as these classes of medications are more commonly used in the current practice.&#x000a0;</p>
      </sec>
      <sec id="article-43010.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>In general, Vasodilators dilate or prevent constriction of the blood vessels,&#x000a0;which&#x000a0;allow greater blood flow to various organs in&#x000a0;the body.<xref ref-type="bibr" rid="article-43010.r3">[3]</xref>&#x000a0;Many vasodilators bind to receptors on endothelial cells of the blood vessel, which stimulate calcium release. Calcium activates the enzyme nitric oxide synthase (NO synthase) and converts L-arginine into NO. It leaves the endothelial cell&#x000a0;via diffusion and enters vascular smooth muscle cells. NO activates GTP and converts it into cGMP. cGMP then stimulates myosin-light chain phosphatase, which removes a single phosphate from myosin and actin filaments. The dephosphorylation of myosin and actin filaments allows vascular smooth muscle relaxation.&#x000a0;</p>
        <p>Below are the specific mechanisms of action for&#x000a0;different&#x000a0;classes of vasodilators:&#x000a0;</p>
        <p><bold>ACE Inhibitors:</bold>&#x000a0;Prevent the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.<xref ref-type="bibr" rid="article-43010.r4">[4]</xref>&#x000a0;&#x000a0;</p>
        <p><bold><bold>Angiotensin Receptor Blockers</bold>: </bold>Prevent&#x000a0;angiotensin II from binding to its receptor.&#x000a0;</p>
        <p><bold>Nitrates:&#x000a0;</bold>Increase the amount of NO in vascular smooth muscle cells, causing vasodilation. Nitrates dilate veins more than arteries and decrease preload.&#x000a0;</p>
        <p><bold>Calcium Channel Blockers: </bold>Block calcium channels in the cardiac and smooth muscles, causing decreased muscle contractility and vasodilation. There are two classes of CCBs: Dihydropyridines (act on the vascular smooth muscle), and non-dihydropyridines (act on the heart).</p>
        <p><bold>Minoxidil:</bold>&#x000a0;Directly relaxes arteriolar smooth muscle, with minimal effect on the vein. Cyclic AMP may mediate its effects.</p>
        <p><bold>Hydralazine:</bold> the exact mechanism is still unknown.</p>
        <p><bold>Beta-Blockers:&#x000a0;</bold>Nebivolol and carvedilol are third-generation &#x003b2;-adrenoreceptor antagonists that have additional endothelium-dependent vasodilating properties.</p>
      </sec>
      <sec id="article-43010.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Vasodilators can be&#x000a0;administered in a variety of ways, including sublingual, IV, oral.<xref ref-type="bibr" rid="article-43010.r5">[5]</xref>&#x000a0;</p>
        <p>Depending on the clinical setting, some routes of administration can be more beneficial than others. For example, in the setting of acute myocardial infarction (MI), patients&#x000a0;will more&#x000a0;likely benefit from sublingual nitroglycerin, as it is absorbed much faster&#x000a0;by the sublingual route and allows the patient to feel more comfortable and often reduces the chest pain.<xref ref-type="bibr" rid="article-43010.r6">[6]</xref>&#x000a0;Whereas for&#x000a0;the&#x000a0;patients who need to reduce their blood pressure in a non-emergent manner, the oral route is an acceptable route of administration.&#x000a0;</p>
        <p>Nitrovasodilators such as nitroprusside and nitroglycerin are frequently used in hypertensive emergencies. Sodium nitroprusside administration is via the intravenous route in such conditions. It&#x000a0;starts blood pressure-lowering action within&#x000a0;one minute or less, and these effects disappear within 10 minutes after discontinuation. Frequent clinical monitoring is necessary&#x000a0;during the administration of this medication.&#x000a0;</p>
        <p>Similar to nitroprusside, nitroglycerin can be used intravenously in certain conditions. It has very similar kinetic, but it produces greater venodilation compared to arteriolar dilation. Extended used is generally avoided due to concerns of tachyphylaxis.</p>
        <p>Severe hypertension&#x000a0;during labor should be treated with intravenous labetalol/hydralazine or oral nifedipine to prevent intracranial hemorrhage or eclampsia.&#x000a0;</p>
        <p>Calcium channel blockers such as clevidipine and nicardipine can be used intravenously in hypertensive emergencies while amlodipine, nifedipine are oral formulations that are used in routine hypertension management.&#x000a0;</p>
        <p>Nebivolol and&#x000a0;carvedilol are taken orally to treat hypertension.</p>
      </sec>
      <sec id="article-43010.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p><bold>ACE Inhibitors:&#x000a0;&#x000a0;</bold>angioedema, dry cough (due to increased bradykinin levels), teratogenicity, hyperkalemia, and hypotension.<xref ref-type="bibr" rid="article-43010.r7">[7]</xref>&#x000a0;There have been studies that show that the use of ACE inhibitors can increase a patient's risk of developing acute pancreatitis.<xref ref-type="bibr" rid="article-43010.r8">[8]</xref>&#x000a0;Examples: enalapril, lisinopril, captopril, ramipril.&#x000a0;</p>
        <p><bold>Angiotensin Receptor Blockers:</bold>&#x000a0;hyperkalemia, hypotension, decrease GFR, teratogenicity.<xref ref-type="bibr" rid="article-43010.r9">[9]</xref>&#x000a0;Examples:&#x000a0;valsartan, losartan, candesartan.</p>
        <p><bold>Calcium Channel Blockers:&#x000a0;</bold>gingival hyperplasia, dizziness, flushing, peripheral edema,&#x000a0;AV block (with Non-dihydropyridines), constipation.<xref ref-type="bibr" rid="article-43010.r10">[10]</xref>&#x000a0;Examples: Dihydropyridines: amlodipine, clevidipine, nicardipine, nifedipine;&#x000a0;Non-dihydropyridines: diltiazem and verapamil&#x000a0;&#x000a0;</p>
        <p><bold>Nitrates:&#x000a0;</bold>reflex tachycardia, headache, flushing, and orthostatic hypotension.<xref ref-type="bibr" rid="article-43010.r11">[11]</xref>&#x000a0;Examples: nitroglycerin, isosorbide mononitrate, isosorbide dinitrate.&#x000a0;Cyanide&#x000a0;toxicity&#x000a0;does not occur with intravenous use, but methemoglobinemia can occur.&#x000a0;</p>
        <p><bold>Hydralazine:&#x000a0;</bold>compensatory tachycardia, headache, angina, SLE-like symptoms (in slow acetylators), fluid retention.&#x000a0;</p>
        <p><bold>Nitroprusside:</bold>&#x000a0;Nitroprusside is metabolized to cyanide,&#x000a0;and it can lead to cyanide toxicity. Toxicity can appear as little as four hours after initiation of infusion.&#x000a0;Potential risk factors for the development of toxicity are&#x000a0;underlying renal impairment,&#x000a0;prolonged treatment period (over 48 hours), and the utilization of a higher dose.<xref ref-type="bibr" rid="article-43010.r12">[12]</xref></p>
        <p><bold>Minoxidil: </bold>hypertrichosis, water retention,&#x000a0;pericarditis that may progress to tamponade.</p>
        <p><bold>Beta-Blockers: </bold>bradycardia, dizziness, headaches, nausea, hypotension, metabolic abnormalities.</p>
        <p>Americal Heart Association/American Stroke Association recommends not reducing blood pressure during the initial 24 hours of ischemic stroke unless it is over 220/120 mm Hg to prevent the worsening of ischemic injury. In the patient with ischemic stroke, BP requires lowering to less than 180/110 mm Hg before administering alteplase with intravenous labetalol/nicardipine.&#x000a0;</p>
      </sec>
      <sec id="article-43010.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p><bold>ACE Inhibitors:&#x000a0;</bold>pregnancy, previous history of angioedema, hereditary angioedema.</p>
        <p><bold>ARBs:&#x000a0;</bold>ARBs&#x000a0;are teratogens and should&#x000a0;not be used in pregnant patients.</p>
        <p><bold>Nitrates:&#x000a0;</bold>Nitrates decrease preload, so the administration of nitrates would be contraindicated in a person having an inferior MI (right ventricular infarction).&#x000a0;</p>
        <p><bold>Calcium Channel Blocker</bold>: severe hypotension, hypersensitivity.</p>
        <p><bold>Hydralazine:&#x000a0;</bold>CAD or angina (it&#x000a0;can cause compensatory tachycardia), mitral valve rheumatic heart disease</p>
        <p><bold>Beta-blockers:</bold> Bradycardia, severe chronic obstructive pulmonary disease, hypotension, cardiogenic shock, and high degree of atrioventricular block.</p>
      </sec>
      <sec id="article-43010.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Vasodilators can be monitored by checking the blood levels of certain drugs. Microvascular monitoring is another way to detect therapeutic levels in patients who are taking vasodilators.<xref ref-type="bibr" rid="article-43010.r13">[13]</xref>&#x000a0;Microvascular&#x000a0;monitoring is the subject of many clinical trials and targets patients before and after vasodilator therapy as a way to detect hemodynamic coherence.&#x000a0;</p>
        <p>After initiation of vasodilators,&#x000a0;blood pressure (both standing and sitting/supine), heart rate should be monitored. If&#x000a0;the patient is on hydralazine&#x000a0;and develops&#x000a0;lupus-like symptoms, check antinuclear antibody (ANA) titers and anti-histone antibody levels. Clinicians should also check renal function values after 2&#x000a0;to 3 weeks after initiation of&#x000a0;ACE Inhibitors and&#x000a0;ARBs. Signs/symptoms of pericardial effusion should require monitoring while patients are on minoxidil.&#x000a0;</p>
      </sec>
      <sec id="article-43010.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p><bold>ACE Inhibitors:&#x000a0;</bold>There are few documented cases of ACE inhibitor overdose.<xref ref-type="bibr" rid="article-43010.r14">[14]</xref>&#x000a0;One case report stated that treating&#x000a0;a patient who overdosed on lisinopril with hemodialysis worked.<xref ref-type="bibr" rid="article-43010.r15">[15]</xref>&#x000a0;In general, supportive care should be established in every case (IV fluids, vasopressors in case of severe hypotension).&#x000a0;</p>
        <p><bold>ARBs:&#x000a0;</bold>Very few cases of ARB overdoses have been reported.<xref ref-type="bibr" rid="article-43010.r16">[16]</xref>&#x000a0;Treating overdose of this medication like any other drug intoxication is recommended.&#x000a0;</p>
        <p><bold>Calcium Channel Blocker</bold>: There is not much evidence on reversing the toxicity of CCBs. One study showed that high-dose insulin and life support were most effective in reversing toxicity.<xref ref-type="bibr" rid="article-43010.r17">[17]</xref></p>
        <p><bold>Nitroprusside: </bold>Sodium thiosulfate is indicated in&#x000a0;the&#x000a0;patient who has cyanide toxicity. It provides sulfur, which converts cyanide into thiocyanate and prevents further adverse effects.<bold>&#x000a0;</bold></p>
        <p><bold>Hydralazine,&#x000a0;Nitrates:</bold>&#x000a0;Very few reported cases of overdose exist to date. Recommendations are to treat these overdoses like any other drug overdose.</p>
        <p><bold>Beta-Blockers:</bold> Glucagon, sodium bicarbonate, and or magnesium may be used.</p>
      </sec>
      <sec id="article-43010.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians need to educate their patients&#x000a0;about&#x000a0;the use of vasodilators. As described above, many adverse side effects exist with vasodilator treatment.&#x000a0;It is the healthcare provider's responsibility to make sure the patient understands the importance of taking their vasodilator medication as prescribed. Undertreatment and/or non-compliance can cause severe hypertension, and this can lead to catastrophic events such as stroke, hypertensive emergency, aortic dissection, and many other preventable diseases.&#x000a0;Also, it is crucial to educate patients&#x000a0;regarding healthy lifestyle habits and dietary modifications. Regular exercise, a healthy and well-balanced diet, and healthy lifestyle&#x000a0;habits (such as&#x000a0;avoidance of&#x000a0;smoking, excessive drinking, or using recreational drugs) can all help a patient's longevity. Nursing will often administer these drugs and need to be familiar with monitoring treatment progress as well as checking on adverse events, reporting any concerns to the clinician. Pharmacists, particularly board-certified cardiology pharmacists, can assist the clinician in agent selection as well as dosing, medication reconciliation, and patient education. These types of interprofessional team actions will improve outcomes with vasodilator therapy. [Level 5]</p>
      </sec>
      <sec id="article-43010.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43010&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43010">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/43010/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=43010">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-43010.s11">
        <fig id="article-43010.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Physiology of Vasodilation of Vascular Smooth Muscle Image designed by Lana Hariri</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2019-10-10__at__7.44.43__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-43010.s12">
        <title>References</title>
        <ref id="article-43010.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loh</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ch'ng</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asmawi</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Yam</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Overview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling Pathways.</article-title>
            <source>Molecules</source>
            <year>2016</year>
            <month>Apr</month>
            <day>15</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>495</fpage>
            <pub-id pub-id-type="pmid">27092479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zsot&#x000e9;r</surname>
                <given-names>TT</given-names>
              </name>
            </person-group>
            <article-title>Vasodilators.</article-title>
            <source>Can Med Assoc J</source>
            <year>1983</year>
            <month>Sep</month>
            <day>01</day>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>424</fpage>
            <page-range>424-8, 432</page-range>
            <pub-id pub-id-type="pmid">6349763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarkin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kaski</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Vasodilator Therapy: Nitrates and Nicorandil.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>367</fpage>
            <page-range>367-378</page-range>
            <pub-id pub-id-type="pmid">27311574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riegger</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitors in congestive heart failure.</article-title>
            <source>Cardiology</source>
            <year>1989</year>
            <volume>76 Suppl 2</volume>
            <fpage>42</fpage>
            <page-range>42-9</page-range>
            <pub-id pub-id-type="pmid">2670220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammer</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Lewandowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drover</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cohane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reece</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>397</fpage>
            <page-range>397-403</page-range>
            <pub-id pub-id-type="pmid">25715047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tri&#x000df;ler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000f6;fling</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>von Knobelsdorff-Brenkenhoff</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pilz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effect of Nitroglycerin on the Performance of MR Coronary Angiography.</article-title>
            <source>J Magn Reson Imaging</source>
            <year>2017</year>
            <month>May</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>1419</fpage>
            <page-range>1419-1428</page-range>
            <pub-id pub-id-type="pmid">27731913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regulski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regulska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stanisz</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Murias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gieremek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wzgarda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niznik</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors.</article-title>
            <source>Curr Pharm Des</source>
            <year>2015</year>
            <volume>21</volume>
            <issue>13</issue>
            <fpage>1764</fpage>
            <page-range>1764-75</page-range>
            <pub-id pub-id-type="pmid">25388457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuoppala</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Enlund</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pulkkinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kastarinen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jyrkk&#x000e4;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Happonen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paajanen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitors and the risk of acute pancreatitis-a population-based case-control study.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>853</fpage>
            <page-range>853-857</page-range>
            <pub-id pub-id-type="pmid">28247528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raebel</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.</article-title>
            <source>Cardiovasc Ther</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>e156</fpage>
            <page-range>e156-66</page-range>
            <pub-id pub-id-type="pmid">21883995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Livada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shiloah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blocker-induced gingival enlargement.</article-title>
            <source>J Hum Hypertens</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-4</page-range>
            <pub-id pub-id-type="pmid">23739159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thadani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Side effects of using nitrates to treat angina.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>667</fpage>
            <page-range>667-74</page-range>
            <pub-id pub-id-type="pmid">16907656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Udeh</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Ting</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arango</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mick</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Delayed presentation of nitroprusside-induced cyanide toxicity.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>1432</fpage>
            <page-range>1432-4</page-range>
            <pub-id pub-id-type="pmid">25841829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ertmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rehberg</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effects of vasodilators on haemodynamic coherence.</article-title>
            <source>Best Pract Res Clin Anaesthesiol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>479</fpage>
            <page-range>479-489</page-range>
            <pub-id pub-id-type="pmid">27931651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trilli</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Lisinopril overdose and management with intravenous angiotensin II.</article-title>
            <source>Ann Pharmacother</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1165</fpage>
            <page-range>1165-8</page-range>
            <pub-id pub-id-type="pmid">7841571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belay</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Nusair</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Apparent lisinopril overdose requiring hemodialysis.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2013</year>
            <month>Jul</month>
            <day>15</day>
            <volume>70</volume>
            <issue>14</issue>
            <fpage>1226</fpage>
            <page-range>1226-9</page-range>
            <pub-id pub-id-type="pmid">23820459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ideno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oiwa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yaguchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Case of olmesartan and amlodipine intoxication].</article-title>
            <source>Chudoku Kenkyu</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>236</fpage>
            <page-range>236-40</page-range>
            <pub-id pub-id-type="pmid">21950027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43010.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guimont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Archambault</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Chauny</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frenette</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Darveau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Sage</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poitras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment for calcium channel blocker poisoning: a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>926</fpage>
            <page-range>926-44</page-range>
            <pub-id pub-id-type="pmid">25283255</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
